European journal of nuclear medicine and molecular imaging · 2026
First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Xiaoai, Xiang Yongzhao, Zalutsky Michael R, Liu Ning, Li Xin, Du Yong, Feng Yutian, Li Feize, Tian Rong
Аннотация
PURPOSE: The prostate-specific membrane antigen (PSMA) inhibitor [211At]YF2 was investigated in a Phase 0 microdose study in patients with metastatic castration resistant prostate cancer (mCRPC). The x-rays from 211At decay were used to assess biodistribution and dosimetry.
METHODS: The biodistribution of [211At]YF2 initially was evaluated in CD-1 mice and human-equivalent estimated radiation doses were calculated using Rapid 3D-RD software. Three patients with PSMA-positive metastases confirmed by [68Ga]Ga-PSMA-11 PET/CT received [211At]YF2 (29.6-44.4 MBq) intravenously. Whole-body planar imaging was performed at 1, 4, and 24 h while SPECT/CT was conducted at 4 and 24 h. Safety assessment was performed for 7 d. Volumes of interest were manually delineated to generate time-activity curves for radiation dosimetry calculation with Rapid 3D-RD software.
RESULTS: Preliminary human dosimetry estimates based on murine data indicated that the kidneys received the highest dose (35.14 mGy/MBq). [211At]YF2 was well tolerated with all adverse events being ≤ Grade 2. High uptake of [211At]YF2 was observed initially in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance. Even at 24 h, pronounced uptake of [211At]YF2 in metastases identified by PSMA-PET was observed in all patients with the most prominent metastasis receiving an average dose of 31.4 mGy/MBq. A kidney dose of 15.3 mGy/MBq was calculated from patient images, considerably lower than predicted from murine biodistribution-derived human dosimetry.
CONCLUSIONS: [211At]YF2 was safely administered to mCRPC patients and metastatic lesions were clearly delineated by 211At imaging. Normal organ accumulation resulted in favorable dosimetry. Based on these results, [211At]YF2 warrants further clinical development.
METHODS: The biodistribution of [211At]YF2 initially was evaluated in CD-1 mice and human-equivalent estimated radiation doses were calculated using Rapid 3D-RD software. Three patients with PSMA-positive metastases confirmed by [68Ga]Ga-PSMA-11 PET/CT received [211At]YF2 (29.6-44.4 MBq) intravenously. Whole-body planar imaging was performed at 1, 4, and 24 h while SPECT/CT was conducted at 4 and 24 h. Safety assessment was performed for 7 d. Volumes of interest were manually delineated to generate time-activity curves for radiation dosimetry calculation with Rapid 3D-RD software.
RESULTS: Preliminary human dosimetry estimates based on murine data indicated that the kidneys received the highest dose (35.14 mGy/MBq). [211At]YF2 was well tolerated with all adverse events being ≤ Grade 2. High uptake of [211At]YF2 was observed initially in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance. Even at 24 h, pronounced uptake of [211At]YF2 in metastases identified by PSMA-PET was observed in all patients with the most prominent metastasis receiving an average dose of 31.4 mGy/MBq. A kidney dose of 15.3 mGy/MBq was calculated from patient images, considerably lower than predicted from murine biodistribution-derived human dosimetry.
CONCLUSIONS: [211At]YF2 was safely administered to mCRPC patients and metastatic lesions were clearly delineated by 211At imaging. Normal organ accumulation resulted in favorable dosimetry. Based on these results, [211At]YF2 warrants further clinical development.